12‐Month Clinical Outcomes Using a Variable‐Loop Circular Catheter for PFA in a Chinese Atrial Fibrillation Population
Pacing and Clinical Electrophysiology · 2026-11 · 49 (11) · 1851-1861
DOI: 10.1111/pace.70294 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pacing and Clinical Electrophysiology, online erschienen am 28.05.2026. Verfasst von Hailong Tao und 11 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Johnson & Johnson MedTech.
Abstract (Originalsprache)
Background
The variable‐loop circular catheter (VLCC) showed promising outcomes in European and US studies, but evidence is limited in Asian populations. afIRE trial assessed 12‐month safety and effectiveness of the VLCC in Chinese patients with symptomatic, drug‐refractory paroxysmal atrial fibrillation (AF).
Methods
AfIRE was a prospective, multicenter, single‐arm trial for adults undergoing first‐time pulmonary vein isolation (PVI) with the VLCC. Primary effectiveness was 12‐month freedom from atrial arrhythmia recurrence (systematically assessed by electrocardiogram and Holter monitoring at 3‐, 6‐, and 12‐months post‐ablation or when symptomatic), repeat ablation, procedural failure, or Class I/III antiarrhythmic drug use. Safety was defined by incidence of primary adverse events (PAEs).
Results
Of 142 patients enrolled, 123 (mean age 57.0 years, 45.5% female) comprised the main‐stage cohort (patients treated with the VLCC after roll in). Median procedure, pulsed field ablation (PFA), and fluoroscopy times were 115.0, 36.1, and 5.0 min, respectively. Acute PVI was achieved in all patients, with 89.4% without acute reconnection and 11.4% undergoing non‐PV ablation. Twelve‐month primary effectiveness success and freedom from symptomatic recurrence were 74.8% and 87.0%, respectively. Safety was favorable, with PAEs in 2 patients (1.6%; vascular complications; unlikely device‐related). Multivariable analysis of the primary endpoint showed that preserved left ventricular ejection fraction (≥ 60%) was associated with 86% reduction in odds of 12‐month atrial arrhythmia recurrence; diabetes, ≥ 9 symptomatic AF episodes, and < 48 valid PFA applications (16 ablations) numerically increased odds of recurrence.
Conclusion
The first Asian VLCC experience demonstrated favorable 12‐month effectiveness and excellent safety, reinforcing reproducibility across global AF populations. Clinical Trial Registration NCT05552963
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Tianjin Medical University General Hospital, Tianjin, China.
- West China Hospital of Sichuan University, Chengdu, China.
- Shanghai General Hospital, Shanghai, China.
- The First Affiliated Hospital of Dalian Medical University, Dalian, China.
- Guangdong Provincial People's Hospital, Guangzhou, China.
ORCID-Profile: Shaowen Liu, Songwen Chen, Xiaomeng Yin, Yumei Xue, Rui Zeng
Förderung
- Johnson & Johnson MedTech
Zitieren
APA
Tao, H., Cai, H., Fu, H., Liu, S., Chen, S., Gao, L., Yin, X., Xue, Y., Liao, H., Zeng, R., Cui, K., & Dong, J. (2026). 12‐Month Clinical Outcomes Using a Variable‐Loop Circular Catheter for PFA in a Chinese Atrial Fibrillation Population. Pacing and Clinical Electrophysiology, 49(11), 1851-1861. https://doi.org/10.1111/pace.70294
Vancouver
Tao H, Cai H, Fu H, Liu S, Chen S, Gao L, et al. 12‐Month Clinical Outcomes Using a Variable‐Loop Circular Catheter for PFA in a Chinese Atrial Fibrillation Population. Pacing and Clinical Electrophysiology. 2026;49(11):1851-1861. doi:10.1111/pace.70294
BibTeX
@article{Tao2026,
author = {Tao, Hailong and Cai, Heng and Fu, Hua and Liu, Shaowen and Chen, Songwen and Gao, Lianjun and Yin, Xiaomeng and Xue, Yumei and Liao, Hongtao and Zeng, Rui and Cui, Kaijun and Dong, Jianzeng},
title = {12‐Month Clinical Outcomes Using a Variable‐Loop Circular Catheter for PFA in a Chinese Atrial Fibrillation Population},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {11},
pages = {1851--1861},
doi = {10.1111/pace.70294}
}
EUVIMED